 Phase II study fluorouracil recombinant interferon advanced colorectal carcinoma phase II clinical trial fluorouracil recombinant interferon rIFN untreated patients measurable metastatic colorectal cancer week continuous intravenous infusion consecutive days Intravenous bolus administration weeks day rIFN Roferon Hoffman-LaRoche Nutley NJ times weeks Patients response week patients study assessable toxicity assessable response Fifteen patients partial response patient clinical complete response overall response rate confidence interval CI Median duration response months range months Seventy percent patients study alive median follow-up duration months Twenty-five percent patients toxicity grade toxicity drug-related death presence sepsis treatment-related seizures experience schedule response rate toxicity Current trials schedule rIFN folinic acid leucovorin single-agent role treatment advanced colorectal carcinomas